CD8A and neoplasm: One can therefore anticipate that 22B12 mAb could exert a double-trigger effect by, on one hand, promoting TNBC tumor cell targeting and, on the other hand, boosting NK cell (and potentially CD8+ T cells) cytotoxicity.